Impact Factor 2019: 1.940 (@Clarivate Analytics)
5-Year Impact Factor: 1.955 (@Clarivate Analytics)
  • Users Online: 194
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2020  |  Volume : 13  |  Issue : 7  |  Page : 288-294

Biosimilars: A novel perspective in diabetes therapy


1 Department of Crop Science, College of Sanghuh Life Science, Konkuk University, Seoul 05029, Republic of Korea
2 Department of Biotechnology, Bharathiar University, Coimbatore, Tamil Nadu 641046, India
3 Translational Research Platform for Veterinary Biologicals, Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Chennai 600051, Tamil Nadu, India

Correspondence Address:
Umadevi Subramanian
Translational Research Platform for Veterinary Biologicals, Tamil Nadu Veterinary and Animal Sciences University, Madhavaram Milk Colony, Chennai 600051, Tamil Nadu
India
Login to access the Email id

Source of Support: This paper was supported by the KU Research Professor Program of Konkuk University, Seoul, South Korea, Conflict of Interest: None


DOI: 10.4103/1995-7645.285827

Get Permissions

Diabetes mellitus, an endocrine disorder, has a wider reach among most of the world population. The incidence of diabetes is high not only among adults but wider-age groups are also becoming susceptible to this disease because of modified food habits and lifestyle changes that are alien to the physiological system. The control of blood glucose level would be the prime focus of all the therapeutic targets, which is achieved through drugs, modified lifestyle, and paleo-based diets. To find a solution to these problems, earlier humans have revolutionized the science with the discovery of insulin from the porcine pancreatic crude extract. Later, developments have been made with artificial recombinant insulin and even insulin analogs that would mimic the physiological basal insulin in controlling the blood sugar levels. Various factors such as cost and logistics for quality delivery to the end-user at various corners of the world have impeded the reach of the original product. Hence, biosimilar insulins that are original insulin analogs were designed to execute similar physiological functions. In the current situation, the use of biosimilars has been approved in various clinical conditions that are very promising in its functions. In the present review, the various developmental phases of biosimilar preparations and the regulations enforced ensuring a quality product in the market through the Food and Drug Administration and the European Medicines Agency have been discussed.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed416    
    Printed15    
    Emailed0    
    PDF Downloaded199    
    Comments [Add]    

Recommend this journal